Abstract
Dementia is the leading cause of disability worldwide among chronic diseases in the elderly and is a major contributor to mortality. Importantly, dementia that develops as a comorbid condition significantly compounds the burden of disease on the person, their caregivers and the health care system. Dementia is a frequent comorbidity of Parkinson’s disease (PD) and about 80% of people with PD will develop dementia during the course of the disease. Incidence of dementia in PD ranges from 54.7 to 107.14 per 1000 person-years while point prevalence estimates range from 19.7 to 35.3%. The range in incidence and point prevalence can be attributed to varying diagnostic criteria, sample biases, and sample size. Nosologically, there is still disagreement on the origins of dementia in PD. Dementia development may be most often caused by the progression of PD-type pathology; however, the occurrence of Alzheimer’s disease (AD)-type pathology suggests that an interplay exists between the genes and proteins associated with PD and AD. Furthermore, these genes and proteins may increase the risk and severity of dementia development in people with PD. Understanding the mechanisms of neurodegeneration in PD and AD may, therefore, improve efforts to manage and treat PD dementia. Given this, it is important to adequately define the frequency of PD dementia for informed decision making, particularly in the areas of aged-care and government health policy.
Keywords: Burden, comorbidity, dementia, epidemiology, impact, Parkinson’s, progression.
CNS & Neurological Disorders - Drug Targets
Title:The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective
Volume: 13 Issue: 7
Author(s): Alyce Russell, Alesya Drozdova, Wei Wang and Meghan Thomas
Affiliation:
Keywords: Burden, comorbidity, dementia, epidemiology, impact, Parkinson’s, progression.
Abstract: Dementia is the leading cause of disability worldwide among chronic diseases in the elderly and is a major contributor to mortality. Importantly, dementia that develops as a comorbid condition significantly compounds the burden of disease on the person, their caregivers and the health care system. Dementia is a frequent comorbidity of Parkinson’s disease (PD) and about 80% of people with PD will develop dementia during the course of the disease. Incidence of dementia in PD ranges from 54.7 to 107.14 per 1000 person-years while point prevalence estimates range from 19.7 to 35.3%. The range in incidence and point prevalence can be attributed to varying diagnostic criteria, sample biases, and sample size. Nosologically, there is still disagreement on the origins of dementia in PD. Dementia development may be most often caused by the progression of PD-type pathology; however, the occurrence of Alzheimer’s disease (AD)-type pathology suggests that an interplay exists between the genes and proteins associated with PD and AD. Furthermore, these genes and proteins may increase the risk and severity of dementia development in people with PD. Understanding the mechanisms of neurodegeneration in PD and AD may, therefore, improve efforts to manage and treat PD dementia. Given this, it is important to adequately define the frequency of PD dementia for informed decision making, particularly in the areas of aged-care and government health policy.
Export Options
About this article
Cite this article as:
Russell Alyce, Drozdova Alesya, Wang Wei and Thomas Meghan, The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective, CNS & Neurological Disorders - Drug Targets 2014; 13 (7) . https://dx.doi.org/10.2174/1871527313666140917122739
DOI https://dx.doi.org/10.2174/1871527313666140917122739 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research Efficacy of Gene Therapy to Restore Cognition in Alzheimer’s Disease: A Systematic Review
Current Gene Therapy Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Mononuclear Phagocyte Accumulation in Visceral Tissue in HIV Encephalitis: Evidence for Increased Monocyte/Macrophage Trafficking and Altered Differentiation
Current HIV Research The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Conference Report: (Annual Advances in Neurorestoratology: A Summary of IANR VI and 10th GCNN Conference, Bucharest, Romania, April 4-7, 2013)
CNS & Neurological Disorders - Drug Targets Structural MRI Biomarkers of Mild Cognitive Impairment from Young Elders to Centenarians
Current Alzheimer Research Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Chronobiological Approaches to Alzheimers Disease
Current Alzheimer Research Chlorella vulgaris: A Multifunctional Dietary Supplement with Diverse Medicinal Properties
Current Pharmaceutical Design Functional Biomedical Images of Alzheimer's Disease a Green's Functionbased Empirical Mode Decomposition Study
Current Alzheimer Research PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry Statins And Stroke
Current Medicinal Chemistry